Press Releases

Press Releases
Date Title and Summary View
Oct 27, 2016 SUNNYVALE, Calif., Oct. 27, 2016 /PRNewswire/ -- With the flu season fast approaching, healthcare providers no longer need to choose between a fast test result or an accurate test result for patients suspected of influenza infection.  Now, they can have both, with Xpert® Xpress Flu/RSV from Cepheid (Nasdaq: CPHD), a new test that delivers refe...
Oct 24, 2016 SUNNYVALE, Calif., Oct. 24, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that antitrust clearances have been received or the requisite waiting periods have expired, as applicable, in the United States, Germany, Austria and South Africa, which comprise all of the governmental approvals required as a closing condition pursuant to the m...
Oct 5, 2016 SUNNYVALE, Calif., Oct. 5, 2016 /PRNewswire/ -- There's now an easier way to confidently rule out bladder cancer recurrence, thanks to a new test from Cepheid (Nasdaq: CPHD), Xpert® Bladder Cancer Monitor, now commercially available in Germany and cleared for commercial availability in all countries accepting the CE Mark.  Bladder cance...
Sep 15, 2016 SUNNYVALE, Calif., Sept. 15, 2016 /PRNewswire/ -- Particularly perilous Clostridium difficile strains are now potentially easier to detect, thanks to expanded reporting  of binary toxin (CDT) gene presence with the leading molecular test for C. difficile from Cepheid (Nasdaq: CPHD).     The presence of binary toxin-producing C. difficile has...
Sep 8, 2016 SUNNYVALE, Calif., Sept. 8, 2016 /PRNewswire/ -- Millions of patients, including newborns, in primary health care settings could gain access to a potentially life-changing test for HIV viral load monitoring thanks to a new development effort from Cepheid (Nasdaq: CPHD), which is being partially funded by a grant from the Bill & Melinda Gates Founda...
Sep 6, 2016 SUNNYVALE, Calif., Sept. 6, 2016 /PRNewswire/ -- Men in the United States can now have easier access to fast and accurate testing for a potentially dangerous sexually transmitted infection, thanks to expanded claims allowed by the Food and Drug Administration (FDA) for the Xpert TV assay by Cepheid (Nasdaq: CPHD), a sensitive urine-based test for T...
Sep 6, 2016 SUNNYVALE, Calif., Sept. 6, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has entered into a definitive agreement with Danaher Corporation (NYSE: DHR) under which Danaher will acquire all of the outstanding shares of Cepheid common stock for $53 per share in cash, or a total enterprise value of approximately $4 billion includi...
Aug 4, 2016 SUNNYVALE, Calif., Aug. 4, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast. Canaccord Genuity Growth Conference, Boston, MAThursday, August 11, 2016 at 9.00 a.m. Eastern Time Baird Global Healthcare Conferenc...
Jul 28, 2016 SUNNYVALE, Calif., July 28, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the second quarter of 2016 of $146.0 million, representing growth of 10%, or 12% on a constant currency basis, from $132.5 million for the second quarter of 2015.  Net loss was $(10.2) million, or $(0.14) per share, which compares to net loss of $(16....
Jul 12, 2016 SUNNYVALE, Calif., July 12, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced the publication of a validation study assessing the use of Xpert HPV (Human Papillomavirus) as a front-line cervical screening test in certain countries outside the United States.  "Performance of a cartridge based assay for the detection of clinically significa...
1
... NextLast